FRANKFURT/LONDON (Reuters) – GSK does not expect uptake of its RSV vaccine will initially be as swift as it was for its blockbuster shingles vaccine, though the company is confident in its new inoculation, Chief Executive Emma Walmsley said on Wednesday.
“I think the uptake on this you need to watch for through the (respiratory syncytial virus, or RSV) season. It won’t be the same rate of build as Shingrix was. But we do think it is a really key pillar,” she said.
Walmsley made the comments to journalists on a conference call. Earlier on Wednesday, GSK raised its 2023 financial guidance after reporting second-quarter earnings that beat estimates.
(Reporting by Ludwig Burger in Frankfurt and Maggie Fick in London; Editing by Andrew Heavens)
